Investigating the effects of ocrelizumab on neurofilament levels and patient satisfaction in multiple sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effects of ocrelizumab treatment on neurofilament light chain (NfL) levels and participant satisfaction after 12 months of therapy. Participants diagnosed with multiple sclerosis, including relapsing and primary progressive forms, will be assessed using a therapy administration satisfaction questionnaire. The study focuses on individuals receiving their first treatment with ocrelizumab subcutaneously, following local prescribing guidelines. By monitoring these outcomes, the study seeks to provide insights into the treatment's impact on both biological markers and patient experience.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of MS
* RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024
* First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab

Exclusion Criteria:

* Participation in interventional studies investigating DMTs for MS
* Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
* Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
* Severe psychiatric disability
* Pregnant women

Where it's running

• Uniklinik RWTH Aachen
  Aachen, Germany Recruiting
• Gesundheitszentrum St. Marien GmbH
  Amberg, Germany Recruiting
• Sächsisches Krankenhaus Arnsdorf
  Arnsdorf, Germany Recruiting
• Neuropraxis im Stadtpalais Dres. Ulzheimer/Herröder/Wessig GbR
  Aschaffenburg, Germany Recruiting
• Neurologie Bad Soden
  Bad Soden, Germany Recruiting
• Neurologische Praxis - Kallmann Neurologie - mszb
  Bamberg, Germany Recruiting

+43 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Reference Study ID Number: ML45551 https://forpatients.roche.com/ No attachments to email below
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728 (U.S. Only)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing Ofatumumab vs Ocrelizumab in Real-World MS Care

  This real-world study tests whether ofatumumab works differently from ocrelizumab for people with multiple sclerosis.

  Recruiting Novartis · East Hanover, New Jersey · NCT07779460

• Ocrelizumab given under the skin after switching from another anti-CD20 therapy

  This study tests a subcutaneous form of ocrelizumab mixed with rHuPH20 in people with relapsing or primary progressive MS who are switching from another anti-CD20 treatment.

  Recruiting at 8 sites Phase 4 Genentech, Inc. · Birmingham, Alabama and 7 other locations · NCT07609719

• Switching to ublituximab for ocrelizumab wearing-off in multiple sclerosis

  This pilot will try switching people with relapsing MS who experience symptom 'wearing off' on ocrelizumab to ublituximab to see if their symptoms improve or return later.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07389590

• Ocrelizumab and GLP‑1 agonists in people with multiple sclerosis

  This project will see if taking GLP‑1 weight‑loss medicines while on ocrelizumab changes progression of disability in adults with multiple sclerosis.

  Recruiting Northwestern University · Chicago, Illinois · NCT07207148

• Assessing the impact of Multiple Sclerosis on physical function while providing continued ocrelizumab treatment

  This study is testing how Multiple Sclerosis affects physical function while continuing treatment with the medication ocrelizumab for people who have already been part of related studies.

  Recruiting at 53 sites Phase 3 Hoffmann-La Roche · Pleven and 55 other locations · NCT06675955

• Comparing Rituximab and Ocrelizumab for Treating Relapsing Multiple Sclerosis

  This study is testing if rituximab works just as well as ocrelizumab for treating relapsing multiple sclerosis in adults.

  Recruiting Phase 3 Amsterdam UMC, location VUmc · Amsterdam · NCT05834855

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.